99久久精品免费观看国产,色网站免费,2021国内精品久久久久久影院,国产免费福利网站,欧美日韩国产精品综合,国内在线精品,国产三级日本三级日产三

CN / EN

News

Technoderma Medicines Receives FDA Approval for Its Atopic Dermatitis Drug IND

Release time: 2022-08-09 Article source: 特科羅

On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing,China, announced that FDA approved the IND application of its novel experimental drug for the topical treatment of Atopic Dermatitis (AD) by issuing a STUDY MAY PROCEED letter on Aug 1st, 2022. Phase I clinical trials will be carried out in several clinical sites in the US.


TDM-180935, TDM’s experimental drug approved in the IND application, is the first one out of several preclinical candidates from the company’s small molecule JAK inhibitor discovery program to enter clinical phase. Based on kinase, cellular and functional assays, TDM-180935 is a JAK1/TYK2 dual inhibitor.


Preclinical MoA studies revealed that TDM-180935 can potently inhibit Th2 immune response characteristic for the initiating phase of AD pathogenesis, as well as Th1 and Th17 immune responses that play a role during the chronic phase, thereby efficiently blocking all major pathogenic pathways leading to AD. The drug demonstrated dose-dependent efficacy on three mouse models for AD and a good safety profile as indicated by GLP toxicology studies.

TDM-180935 is the company’s second IND approval by FDA. Previously, TDM-105795, a small molecule thyroid hormone receptor agonist for the topical treatment of Androgenetic Alopecia (AGA) has been approved for phase I clinical trials in April 2021. Phase I trials of TDM-105795 will be completed in Q4 2022 and phase II trials are scheduled to start in Dec 2022 or Jan 2023.

德格县| 斗六市| 邢台县| 龙岩市| 二手房| 辉县市| 安丘市| 扬州市| 巴林左旗| 武清区| 登封市| 新野县| 崇州市| 泸西县| 鄄城县| 花莲县| 新兴县| 东平县| 马鞍山市| 增城市| 永年县| 江达县| 孝感市| 东阿县| 荥经县| 保康县| 辰溪县| 渑池县| 晴隆县| 高尔夫| 沁源县| 鹰潭市| 阳春市| 灵台县| 平果县| 夹江县| 汝州市| 肥西县| 许昌县| 前郭尔| 托克托县|